West China Journal of Stomatology ›› 2020, Vol. 38 ›› Issue (1): 17-22.doi: 10.7518/hxkq.2020.01.004

Previous Articles     Next Articles

Effect of the focal adhesion kinase inhibitor TAE226 on the epithelial-mesenchymal transition in human oral squamous cell carcinoma cell line

Zou Xiangyu1,2,Zeng Qin1,2,Liu Ping3,Nie Minhai1,2()   

  1. 1. Dept. of Periodontics and Oral Medicine, The Affiliated Hospital of Stomatology, Southwest Medical University, Luzhou 646000, China
    2. Laboratory for Reconstraction and Regeneration of Oral and Maxillofacial Region, Southwest Medical University, Luzhou 646000, China
    3. Dept. of Stomatology, Luohu People’s Hospital of Shenzhen, Shenzhen 518000, China
  • Received:2019-03-21 Revised:2019-08-19 Online:2020-02-01 Published:2020-02-06
  • Contact: Minhai Nie E-mail:517094363@qq.com
  • Supported by:
    Sichuan Science and Technology Program(2018JY0401)

Abstract:

Objective To study the effect of the focal adhesion kinase inhibitor TAE226 on epithelial-mesenchymal transition (EMT) in human oral squamous cell carcinoma (OSCC) cell line. Methods HSC-3 and HSC-4 cells were cultured with TAE226 under different concentrations (0, 1, 5, and 10 μmol·L-1) for 24, 48, and 72 h. Real-time quantitative polymerase chain reaction was performed to detect the mRNA expressions of E-cadherin and Vimentin. The protein expressions of E-cadherin and Vimentin were determined by Western blot assay after 48 h of TAE226 treatment. Results Real-time quantitative polymerase chain reaction showed that increasing the TAE226 dose and reaction time resulted in increased and decreased E-cadherin and Vimentin mRNA expressions, respectively (P<0.05). Western blot assays showed that increasing the TAE226 dose resulted in increased and decreased E-cadherin and Vimentin protein expressions, respectively (P<0.05). Conclusion TAE226, which is expected to be an effective drug for OSCC treatment, can effectively inhibit the EMT of the OSCC cell line.

Key words: focal adhesion kinase inhibitor TAE226, epithelial-mesenchymal transition, oral squamous cell carcinoma

CLC Number: